Impact of Teledermoscopy on Melanoma Diagnosis and Triage Efficiency in Northern Sweden
DOI:
https://doi.org/10.2340/actadv.v106.44052Keywords:
cutaneous melanoma, malignant melanoma, dermoscopy, skin cancer, teledermoscopy, telemedicineAbstract
The increasing incidence of cutaneous melanomas requires safe, efficient diagnostic methods to improve patient outcomes while optimizing healthcare resource utilization. Teledermoscopy was incorporated into clinical practice in 2014 in northern Sweden to improve diagnostic accuracy of cutaneous lesions and increase access to specialist dermatology care. This study aimed to evaluate whether teledermoscopy has led to earlier and more efficient diagnostics of cutaneous melanomas. Data on all excised pigmented cutaneous lesions from County Council of Västerbotten analysed at the Department of Clinical Pathology from 2010 to 2019 were collected. Before the introduction of teledermoscopy, the mean Breslow thickness was significantly higher (1.44 mm vs 1.08 mm, p=0.008), the proportion of Breslow ≤ 0.8 mm significantly lower (51.4% vs 70.6%, p< 0.001), and the mean Number Needed to Excise (23.32 vs 9.01, p< 0.001) significantly higher before the introduction of teledermoscopy. This indicates that teledermoscopy contributes to earlier and more efficient melanoma diagnosis.
Downloads
References
Swedish Melanoma Registry. The Swedish National Quality Register for Cutaneous Malignant Melanoma SweMR, 1990–2023. Available from https://cancercentrum.se/download/18.3de350c219545ea25bd22999/1741083699568/arsrapport-swemr-1990-2023.pdf
Malmberg C, Steen Carlsson K. Samhällskostnaderna för hudcancer i Sverige. IHE RAPPORT 2025:5, IHE: Lund. Available from https://ihe.se/en/rapport/samhallskostnaderna-for-hudcancer-i-sverige-2/
Petty AJ, Ackerson B, Garza R, Peterson M, Liu B, Green C, et al. Meta-analysis of number needed to treat for diagnosis of melanoma by clinical setting. J Am Acad Dermatol 2020; 82: 1158–1165. DOI: https://doi.org/10.1016/j.jaad.2019.12.063
Argenziano G, Cerroni L, Zalaudek I, Staibano S, Hofmann-Wellenhof R, Arpaia N, et al. Accuracy in melanoma detection: a 10-year multicenter survey. J Am Acad Dermatol 2012; 67: 54–59. DOI: https://doi.org/10.1016/j.jaad.2011.07.019
Hajdarevic S, Hornsten A, Sundbom E, Isaksson U, Schmitt-Egenolf M. Health-care delay in malignant melanoma: various pathways to diagnosis and treatment. Dermatol Res Pract 2014; 2014: 294287. DOI: https://doi.org/10.1155/2014/294287
Swedish Melanoma Registry. The Swedish National Quality Register for Cutaneous Malignant Melanoma SweMR [cited 2025 Sept 15]. Available from: https://statistik.incanet.se/Hudmelanom/.
Zazo V, Boman A, Andersson N. Diagnostic accuracy and safety of teledermoscopy for cutaneous melanoma triage in Northern Sweden. Acta Derm Venereol 2024; 104: adv15302. DOI: https://doi.org/10.2340/actadv.v104.15302
Ahnlide I, Nielsen K, Bjellerup M. Diagnosis of pigmented skin tumours in a dermatological setting: different aspects of the number needed to excise as a measure of efficiency. Acta Derm Venereol 2014; 94: 683–686. DOI: https://doi.org/10.2340/00015555-1831
Isaksson K, Mikiver R, Eriksson H, Lapins J, Nielsen K, Ingvar C, et al. Survival in 31 670 patients with thin melanomas: a Swedish population-based study. Br J Dermatol 2021; 184: 60–67. DOI: https://doi.org/10.1111/bjd.19015
Lo SN, Scolyer RA, Thompson JF. Long-term survival of patients with thin (T1) cutaneous melanomas: a Breslow thickness cut point of 0.8 mm separates higher-risk and lower-risk tumors. Ann Surg Oncol 2018; 25: 894–902. DOI: https://doi.org/10.1245/s10434-017-6325-1
Elder DE, Massi D, Scolyer RA, Willemze R. WHO classification of skin tumours. 4th ed. Lyon: IARC; 2018.
Public Health Agency of Sweden [Internet]. Malignant melanoma, deaths by sex, region, and year, number per 100 000 inhabitants. [Cited 2025 Sept 15]. Available from: https://fohm-app.folkhalsomyndigheten.se/Folkhalsodata/pxweb/sv/A_Folkhalsodata/A_Folkhalsodata__A_Mo8__Halsoutfall__04Cancer__04.05Malmcanc/MalmcancReg.px/
Schultz K, Ivert LU, Lapins J, Sartorius K, Johansson EK. Lead time from first suspicion of malignant melanoma in primary care to diagnostic excision: a cohort study comparing teledermatoscopy and traditional referral to a dermatology clinic at a tertiary hospital. Dermatol Pract Concept 2023; 13: e2023018. DOI: https://doi.org/10.5826/dpc.1301a18
Erdmann F, Lortet-Tieulent J, Schuz J, Zeeb H, Greinert R, Breitbart EW, et al. International trends in the incidence of malignant melanoma 1953–2008: are recent generations at higher or lower risk? Int J Cancer 2013; 132: 385–400. DOI: https://doi.org/10.1002/ijc.27616
Tryggvadottir L, Gislum M, Hakulinen T, Klint A, Engholm G, Storm HH, et al. Trends in the survival of patients diagnosed with malignant melanoma of the skin in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol 2010; 49: 665–672. DOI: https://doi.org/10.3109/02841861003702528
Helgadottir H, Isaksson K, Fritz I, Ingvar C, Lapins J, Hoiom V, et al. Multiple primary melanoma incidence trends over five decades: a nationwide population-based study. J Natl Cancer Inst 2021; 113: 318–328. DOI: https://doi.org/10.1093/jnci/djaa088
Sacchetto L, Zanetti R, Comber H, Bouchardy C, Brewster DH, Broganelli P, et al. Trends in incidence of thick, thin and in situ melanoma in Europe. Eur J Cancer 2018; 92: 108–118. DOI: https://doi.org/10.1016/j.ejca.2017.12.024
Helgadottir H, Mikiver R, Schultz K, Nielsen K, Portelli F, Lapins J, et al. melanoma incidence and mortality trends among patients aged 59 years or younger in Sweden. JAMA Dermatol 2024; 160: 1201–1210. DOI: https://doi.org/10.1001/jamadermatol.2024.3514
Aitken JF, Youlden DR, Baade PD, Soyer HP, Green AC, Smithers BM. Generational shift in melanoma incidence and mortality in Queensland, Australia, 1995–2014. Int J Cancer 2018; 142: 1528–1535. DOI: https://doi.org/10.1002/ijc.31141
Paulson KG, Gupta D, Kim TS, Veatch JR, Byrd DR, Bhatia S, et al. Age-specific incidence of melanoma in the United States. JAMA Dermatol 2020; 156: 57–64. DOI: https://doi.org/10.1001/jamadermatol.2019.3353
Scoggins CR, Ross MI, Reintgen DS, Noyes RD, Goydos JS, Beitsch PD, et al. Gender-related differences in outcome for melanoma patients. Ann Surg 2006; 243: 693–698; discussion 698–700. DOI: https://doi.org/10.1097/01.sla.0000216771.81362.6b
Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622–3634. DOI: https://doi.org/10.1200/JCO.2001.19.16.3622
Blum A, Ingvar C, Avramidis M, von Kannen A, Menzies SW, Olsson H, et al. Time to diagnosis of melanoma: same trend in different continents. J Cutan Med Surg 2007; 11: 137–144. DOI: https://doi.org/10.2310/7750.2007.00023
Published
How to Cite
License
Copyright (c) 2026 Antonia Lindfors, Virginia Zazo, Daniel Nosek, Per Hallberg, Zinaida Bucharbajeva, Nina Lycksell, Nirina Andersson
This work is licensed under a Creative Commons Attribution 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
